NCT03339713View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

PHASE2CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

July 23, 2018

Study Completion Date

July 23, 2018

Conditions

Healthy

Interventions

BIOLOGICAL

Ad26.RSV.preF

Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.

BIOLOGICAL

Fluarix

Fluarix will be administered as intramuscular injection.

BIOLOGICAL

Placebo

Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.

Trial Locations (1)

29464

Coastal Carolina Research Center, Mt. Pleasant

All Listed Sponsors

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03339713 - A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health | Biotech Hunter | Biotech Hunter